June 1, 2021Open Access

CDKN2A Alterations and Response to Immunotherapy in Solid Tumors

Key Points

Key points are not available for this paper at this time.

Abstract

Our data show that CDKN2A GAs were associated with reduced benefit from ICI therapy in urothelial carcinoma as well as changes in the tumor-immune microenvironment.

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper

Cite This Study

Adib et al. (Tue,) studied this question.

synapsesocial.com/papers/69dcca0fc099bcfdbb133a73 https://doi.org/https://doi.org/10.1158/1078-0432.ccr-21-0575

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Comprehensive molecular characterization of gastric adenocarcinoma2014 · 6,521 citations
2Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028)2017 · 6 citations
3Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations2020 · 31 citations
4Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors2020 · 79 citations
5A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma2019 · 76 citations

اسأل الذكاء الاصطناعي

Bookmark

View Full Paper